KDR and cancer: Among the major groups of targeted drugs currently approved for use against metastatic RCC, sorafenib and sunitinib are two representatives of the former, inhibiting tyrosine kinase VEGFR-2 and PDGFR-β on cancer cell, endothelial cells and pericytes, respectively [56].